Mary Kay Inc. Advocates for Women’s Empowerment, Safe and Dignified Work Environments at International Women’s Forum – TIME’S UP UK Virtual Event
22.7.2020 15:00:00 EEST | Business Wire | Press release
On May 21st, Mary Kay Inc., an advocate for global women’s empowerment and entrepreneurship, joined the International Women's Forum (IWF) Virtual Conference, for a session titled “SAFE SETS: An online panel discussion with TIME’S UP UK.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200722005187/en/
Carolyn Passey, General Manager, Mary Kay United Kingdom & Ireland (Photo: Mary Kay Inc.)
The live session tackled the ever-present issue for women across the globe: sexual harassment and abuse in the workplace. TIME’S UP UK stressed the critical importance of changing the culture to ensure a safe workplace free from harassment and referred to the work being done to define safety for women in film through intimacy guidelines.
The speakers with TIME’S UP UK included:
- Dame Heather Rabbatts, TIME’S UP UK Chair, Managing Director of Cove Pictures; Chair of Soho Theatre and non-executive board member for Arts Alliance.
- Ita O’Brien, the UK’s leading Intimacy Coordinator and founder of Intimacy on Set, her company through which she has been developing best practices regarding intimacy and nudity in film, television and theatre and through which she trains Intimacy Coordinators all over the world.
“TIME’S UP’s efforts will help bring about broader change for women in the workplace – worldwide and across industries,” said Carolyn Passey, General Manager of Mary Kay UK and Ireland. “As one of the world’s leading champions of women’s empowerment, Mary Kay is proud to support, through IWF, women leaders who are standing up to give fellow women a voice, help them embrace their identity and define their own boundaries.”
“What was increasingly apparent throughout the conversation was how #MeToo and TIME’S UP have had a huge and positive influence for changing the way productions work, how they are shifting to better practices in many new ways, and in particular with the new role of the Intimacy Coordinator,” said Dame Heather Rabbatts. “The conversation about safe sets is about how we make the culture shift, one industry after another, until we don’t need to have this conversation ever again.”
“‘Yes’, means yes, ‘no’ means no, and ‘maybe’ means no – we celebrate and embrace the ‘no’,” emphasized Ita O’Brien, when talking of the process during which actors get to voice their comfort level when shooting intimate scenes. The firm founded by O’Brien, Intimacy on Set, has put in place guidelines to provide clear lanes of communication and consent not only between actors, but also everyone else involved in shooting intimate and emotional scenes. “Clear boundaries actually create freedom and help understand what is right for you.”
“This line goes to the heart of the matter, and how we are all learning to express where our boundaries lie, and not being afraid to share them,” concluded Dame Heather Rabbatts. “Having in place some mechanisms to protect yourself is very important, so that we know we can exercise a ‘no’. This should empower us in all the sticky and difficult situations that happen in life, whether personal or professional.”
“It is invigorating to witness the influential work that female thought leaders and advocates have achieved over the past several years for the advancement of women’s safety and security in the workplace. These women, some of the most influential thought leaders in the United Kingdom, are on a mission to champion the next generation of women to become tomorrow’s leaders,” said Marty Wikstrom, Member of IWF U.K. and co-chair of the Cornerstone Conference. “IWF has been advancing women’s leadership and championing equality worldwide since 1974, and Mary Kay has been an advocate of women’s entrepreneurship and leadership since 1963. This session reflects a meeting of the minds, and we are proud to showcase this female-fueled partnership.”
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.
About International Women’s Forum (IWF) and the Leadership Foundation
IWF is an invitation-only membership organization of more than 7,000 diverse and accomplished women from 33 nations on six continents. IWF advances women’s leadership and champions equality worldwide by connecting accomplished women both globally and locally. Members include Fortune 500 executives, government leaders from the local to sovereign level, international nonprofit leaders, and luminaries from the academy, arts and sciences: www.iwforum.org.
About TIME’S UP UK
TIME’S UP is an organisation that insists on safe, fair and dignified work for women of all kinds. In response to the growing TIME’S UP movement in the US, a group of UK-based women: actors, producers, writers and others from the film, TV and theatre industries catalysed a sister initiative in the UK. For maximum impact it is set up under the TIME’S UP brand and aims to amplify and reinforce the message already promoted in the US.
The UK movement seeks to build on key elements of the solidarity letter released by TIME’S UP and the statement by the activists attending the Globes, which emphasised the need to highlight the connections between the harassment revelations in Hollywood and the wider, systematic nature of harassment and violence against women across all industries, contexts and countries with the recognition that this issue is universal. We seek strength in unity and maximum cooperation. The activist statement also flagged the ways in which the TIME’S UP initiative joins an ever-growing collective of organisations, movements and leaders working to end gender-based violence. The UK work stands absolutely in solidarity with existing movements: TIME’S UP UK is also now a recently formed charity, and as a charity we can only continue the work with support and donations. We all appreciate that we are experiencing unprecedented challenges but as TIME’S UP focusses on safety for all women in the workplace, which now includes the home, we hope you will be able to support us: www.timesupuk.org.
About Intimacy on Set
Founded in 2018, Intimacy on Set provides services to TV, film, & theatre when dealing with intimacy, sexual content, and nudity. Its Founder, UK’s leading Intimacy Coordinator, Ita O’Brien, pioneered the role of the Intimacy Coordinator and since 2014 has been developing best practice Intimacy on Set Guidelines, which have been widely adopted in the industry. Championed by the TIME’S UP movement and others, the firm advocates for safe, fair and dignified work for everyone. O’Brien has worked on numerous high profile productions including Normal People (BBC3/Hulu), Sex Education 1&2 (Netflix), Gangs of London (Sky Atlantic), The Great (Hulu) and I May Destroy You (BBC/HBO), and has been widely covered in the national and international media as the leading spokesperson in this space: www.intimacyonset.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005187/en/
Contact information
Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
